The relationship between glycine transporter 1 occupancy and the effects of the glycine transporter 1 inhibitor RG1678 or ORG25935 on object retrieval performance in scopolamine impaired rhesus monkey.
Reduced NMDA receptor functioning is hypothesized to underlie the cognitive and negative symptoms associated with schizophrenia. However, because direct activation of the NMDA receptor is accompanied by neurotoxicity, mechanisms that activate the glycine co-agonist site on the NMDA receptor could carry greater therapeutic potential. In the current study, the effects of two glycine transporter 1 (GlyT1) inhibitors, RG1678 and ORG25935, were characterized in the object-retrieval detour (ORD) task in scopolamine-impaired rhesus monkeys and, using positron emission tomography (PET), the GlyT1 occupancy to efficacy relationship of each compound was established. Scopolamine exerted a significant decrease in accuracy in the ORD task. Lower doses of RG1678 (0.3 and 1.0 mg/kg, p.o.) significantly attenuated the impact of scopolamine, whereas the highest dose tested (1.8 mg/kg) did not. The predicted GlyT1 occupancies of RG1678 at the effective doses were ~10 and 30 %. ORG25935 (0.1, 0.3, and 1 mg/kg, p.o.) also significantly attenuated the impact of scopolamine on the ORD task, whereas 3 mg/kg did not. The predicted GlyT1 occupancies of ORG25935 at the effective doses ranged from 16 to 80 %. These data suggest that GlyT1 inhibitors have the potential to improve performance on prefrontal cortex-dependent tests such as the ORD task, but that efficacy is lost when higher occupancies are achieved. Importantly, recent Ph2B data published by Roche suggests that low but not high doses of RG1678 improved negative symptoms in patients with schizophrenia, highlighting the potential translational nature of the current preclinical findings.
St. Jude Children's Research Hospital, Memphis, TN, 38105-3678, USA.
Donnie
D
Eddins
Terence G
TG
Hamill
Vanita
V
Puri
Christopher E
CE
Cannon
Jeffrey A
JA
Vivian
Sandra M
SM
Sanabria-Bohórquez
Jacquelynn J
JJ
Cook
John A
JA
Morrow
Fiona
F
Thomson
Jason M
JM
Uslaner
D000818:Animals; D002491:Central Nervous System Agents / Q000493:pharmacokinetics / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D050487:Glycine Plasma Membrane Transport Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D008253:Macaca mulatta; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D018727:Muscarinic Antagonists / Q000009:adverse effects*; D010879:Piperazines / Q000493:pharmacokinetics / Q000494:pharmacology*; D049268:Positron-Emission Tomography; D012601:Scopolamine / Q000009:adverse effects*; D013450:Sulfones / Q000493:pharmacokinetics / Q000494:pharmacology*; D013647:Task Performance and Analysis; D013764:Tetrahydronaphthalenes / Q000493:pharmacokinetics / Q000494:pharmacology*
C550631:(4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl)(5-methanesulfonyl-2-(2,2,2-trifluoro-1-methylethoxy)phenyl)methanone; D002491:Central Nervous System Agents; D050487:Glycine Plasma Membrane Transport Proteins; D018727:Muscarinic Antagonists; C520612:N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2-ylmethyl)aminomethylcarboxylic acid; D010879:Piperazines; D013450:Sulfones; D013764:Tetrahydronaphthalenes; D012601:Scopolamine